Has dose-dense chemotherapy met an ICONic end?

Emily M. Hinchcliff, Larissa A. Meyer, Shannon N. Westin

Research output: Contribution to journalComment/debatepeer-review

2 Scopus citations
Original languageEnglish (US)
Pages (from-to)869-870
Number of pages2
JournalThe Lancet Oncology
Volume21
Issue number7
DOIs
StatePublished - Jul 2020

Funding

EMH reports no competing interests. LAM reports research funding from AstraZeneca. SNW reports personal fees for consulting from AstraZeneca, Circulogene, Clovis Oncology, Merck, Novartis, Pfizer, Roche/Genentech, GSK/Tesaro, and Eisai and research funding to her institution from ArQule, AstraZeneca, Bayer, Clovis Oncology, Cotinga Pharmaceuticals, Novartis, Roche/Genentech, and GSK/Tesaro. EMH is supported by a National Institutes of Health (NIH) T32 grant (CA101642). LAM is supported by a NIH K07 grant (CA201013). SNW is supported by NIH SPORE in Ovarian Cancer (1P50CA217685-01) and a Gynecologic Oncology Group Foundation Scholar Investigator Award.

ASJC Scopus subject areas

  • Oncology

Cite this